Mechanisms of p53 restriction in merkel cell carcinoma cells are independent of the merkel cell polyoma virus T antigens

Journal of Investigative Dermatology

Volumn 133, Issue 10, 2013, Pages 2453-2460

  Houben, Roland ^a   Dreher, Christina ^a   Angermeyer, Sabrina ^a   Borst, Andreas ^a   Utikal, Jochen ^b,c   Haferkamp, Sebastian ^a   Peitsch, Wiebke K ^c   Schrama, David ^a,d   Hesbacher, Sonja ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; VIRUS T ANTIGEN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN CELL; MERKEL CELL TUMOR; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE;

EID: 84884283691     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.169     Document Type: Article

References (54)

1. Bargonetti J, Reynisdottir I, Friedman PN et al. (1992) Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 6: 1886-98
2. Becker JC (2010) Merkel cell carcinoma. Ann Oncol 21(Suppl 7):vii81-5, vii81-vii85
3. Blagosklonny MV (1997) Loss of function and p53 protein stabilization. Oncogene 15: 1889-93
4. Cheng J, DeCaprio JA, Fluck MM et al. (2009) Cellular transformation by Simian Virus 40 and Murine Polyoma Virus T antigens. Semin Cancer Biol 19: 218-28
5. Feng H, Shuda M, Chang Y et al. (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319: 1096-100
6. Gjoerup O, Chang Y (2010) Update on human polyomaviruses and cancer. Adv Cancer Res 106: 1-51
7. Gjoerup O, Chao H, DeCaprio JA et al. (2000) pRB-dependent, J domainindependent function of simian virus 40 large T antigen in override of p53 growth suppression. J Virol 74: 864-74
8. Green DR, Chipuk JE (2006) p53 and metabolism: Inside the TIGAR. Cell 126: 30-2
9. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-908
10. Hodgson NC (2005) Merkel cell carcinoma: changing incidence trends. J Surg Oncol 89: 1-4
11. Houben R, Adam C, Baeurle A et al. (2012a) An intact retinoblastoma proteinbinding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer 130: 847-56
12. Houben R, Grimm J, Willmes C et al. (2012b) Merkel cell carcinoma and Merkel cell polyomavirus: evidence for hit-and-run oncogenesis. J Invest Dermatol 132: 254-6
13. Houben R, Hesbacher S, Schmid CP et al. (2011) High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One 6:e22096
14. Houben R, Ortmann S, Schrama D et al. (2007) Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol 127: 2116-22
15. Houben R, Shuda M, Weinkam R et al. (2010) Merkel cell polyomavirusinfected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 84: 7064-72
16. Jiang D, Srinivasan A, Lozano G et al. (1993) SV40 T antigen abrogates p53- mediated transcriptional activity. Oncogene 8: 2805-12
17. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303
18. Lassacher A, Heitzer E, Kerl H et al. (2008) p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. J Invest Dermatol 128: 1788-96
19. Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-50
20. Lemos B, Nghiem P (2007) Merkel cell carcinoma: more deaths but still no pathway to blame. J Invest Dermatol 127: 2100-3
21. Leonard JH, Dash P, Holland P et al. (1995) Characterisation of four Merkel cell carcinoma adherent cell lines. Int J Cancer 60: 100-7
22. Levine AJ (2009) The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 384: 285-93
23. Lin JY, Simmons DT (1991) The ability of large T antigen to complex with p53 is necessary for the increased life span and partial transformation of human cells by simian virus 40. J Virol 65: 6447-53
24. Michael D, Oren M (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13: 49-58
25. Oliner JD, Pietenpol JA, Thiagalingam S et al. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-60
26. Pabla N, Huang S, Mi QS et al. (2008) ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-83
27. Patton JT, Mayo LD, Singhi AD et al. (2006) Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 66: 3169-76
28. Pectasides D, Pectasides M, Psyrri A et al. (2006) Cisplatin-based chemotherapy for merkel cell carcinoma of the skin. Cancer Invest 24: 780-5
29. Petitjean A, Mathe E, Kato S et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-9
30. Pipas JM, Levine AJ (2001) Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 11: 23-30
31. Poulsen M, Rischin D, Walpole E et al. (2003) High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study-TROG 96:07. J Clin Oncol 21: 4371-6
32. Poulsen MG, Rischin D, Porter I et al. (2006) Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys 64: 114-9
33. Quartin RS, Cole CN, Pipas JM et al. (1994) The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells. J Virol 68: 1334-41
34. Rodig SJ, Cheng J, Wardzala J et al. (2012) Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 122: 4645-53
35. Roemer K (1999) Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem 380: 879-87
36. Ronan SG, Green AD, Shilkaitis A et al. (1993) Merkel cell carcinoma: in vitro and in vivo characteristics of a new cell line. J Am Acad Dermatol 29: 715-22
37. Rushton JJ, Jiang D, Srinivasan A et al. (1997) Simian virus 40 T antigen can regulate p53-mediated transcription independent of binding p53. J Virol 71: 5620-3
38. Sastre-Garau X, Peter M, Avril MF et al. (2009) Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol 218: 48-56
39. Secchiero P, Bosco R, Celeghini C et al. (2011) Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 17: 569-77
40. Sherr CJ (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-73
41. Shuda M, Feng H, Kwun HJ et al. (2008) T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 105: 16272-7
42. Sihto H, Kukko H, Koljonen V et al. (2011) Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma. Clin Cancer Res 17: 4806-13
43. Song H, Xu Y (2007) Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 6: 1570-3
44. Soussi T (2007) p53 alterations in human cancer: more questions than answers. Oncogene 26: 2145-56
45. Tai PT, Yu E, Winquist E et al. (2000) Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18: 2493-9
46. Tovar C, Rosinski J, Filipovic Z et al. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103: 1888-93
47. Tseng HY, Jiang CC, Croft A et al. (2010) Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol Cancer Ther 9: 3363-74
48. Van Gele M, Kaghad M, Leonard JH et al. (2000) Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer 82: 823-6
49. Van Gele M, Leonard JH, Van RN et al. (2002) Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma. Int J Cancer 101: 137-45
50. van Oijen MG, Slootweg PJ (2000) Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 6: 2138-45
51. Voog E, Biron P, Martin JP et al. (1999) Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85: 2589-95
52. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604
53. Wischhusen J, Melino G, Weller M (2004) p53 and its family members - reporter genes may not see the difference. Cell Death Differ 11: 1150-2
54. Zhang J, Cho SJ, Shu L et al. (2011) Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev 25: 1528-43